BioSpace News Archive

Press Releases

/C O R R E C T I O N -- Nanoscope Therapeutics/

October 1, 2026

·

7 min read

Start of negative growth trend. Worsening forecast. Cessation of rise inertia, not enough power energy. The risk of recession and sliding into a crisis

Obesity

Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again

Despite meeting the primary endpoints in a Phase 3 trial, shares of Zealand Pharma dropped in premarket trading Thursday as the up to 9.8% weight loss reflected inferior loss to that generated by competitors.

October 1, 2026

·

2 min read

·

Heather McKenzie

Layoffs

Foghorn lays off 40% of staff after Lilly collaboration ends

Foghorn Therapeutics and Eli Lilly teamed up in 2021 to develop and commercialize oncology products. The biotech’s layoffs will leave the company with 65 employees as it refocuses on its proprietary portfolio programs.

October 1, 2026

·

2 min read

·

Angela Gabriel

Illustration of a yellow envelope on a blue background with a read warning symbol

Manufacturing

Fresenius Kabi manufacturing plant hit with FDA warning letter after adverse events

Patients had adverse events after receiving a Fresenius Kabi medicine that experienced manufacturing deviations.

October 1, 2026

·

2 min read

·

Nick Paul Taylor

Businessman lost the way to move up stock illustration

Idiopathic pulmonary fibrosis

BMS reports liver injury events in lung disease program, with key readout near

Bristol Myers Squibb will soon release Phase 3 data for admilparant that could make or break Contineum Therapeutics’ rival product. But reports of a death due to liver injury in the pharma’s program have caused some unease about the drug class.

October 1, 2026

·

3 min read

·

Annalee Armstrong

Press Releases

Imbed Biosciences’ DualGuard™ Silver-Gallium Matrix Safety Study Now Registered on ClinicalTrials.gov

October 1, 2026

·

6 min read

Businessmen successfully meeting their goals concept. Properly grouped with high resolution jpg. More Concept Series Lightbox

Drug Development

Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease

Merck has revealed detailed data for tulisokibart from a mid-stage trial in hidradenitis suppurativa that analysts say could help carve out a place in a crowded market that already includes AbbVie’s Humira and UCB’s Bimzelx.

October 1, 2026

·

2 min read

·

Tristan Manalac

Press Releases

sam(R) 3.0 Now Covered Under Workers’ Compensation and Secondary Insurance for Professional and Collegiate Athletes

October 1, 2026

·

2 min read

Press Releases

National Eczema Association Publishes First Comprehensive National and State-Level Report on Atopic Dermatitis